Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?

Yes, ready for primetime in the clinic

Date

19 Sep 2021

Session

Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?

Presenters

Paolo Ascierto

Authors

P.A. Ascierto

Author affiliations

  • Melanoma, Cancer Immunotherapy & Developmental Therapeutics, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction by the chair

Presenter: Omid Hamid

Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?

Resources:

Slides

Webcast

Polling 2 (led by chair)

Presenter: Omid Hamid

Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?

Resources:

Slides

Webcast

Q&A

Presenter: Omid Hamid

Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.